Clinical Trials Logo

Clinical Trial Summary

This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels. Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.


Clinical Trial Description

IXT-m200 is a monoclonal antibody that binds to methamphetamine in the blood. The main purpose of this study is to look at the effects of IXT-m200 on the pharmacokinetics of methamphetamine and on methamphetamine liking effects. Additionally, the study will determine IXT-m200 pharmacokinetics, safety and tolerability in subjects with methamphetamine use disorder. Qualified subjects will receive a single dose of IXT-m200 followed by up to 4 methamphetamine challenge doses. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03336866
Study type Interventional
Source InterveXion Therapeutics, LLC
Contact
Status Completed
Phase Phase 1/Phase 2
Start date May 3, 2018
Completion date March 9, 2021

See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse Phase 2
Not yet recruiting NCT05593796 - Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder N/A
Completed NCT02907853 - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa N/A
Recruiting NCT04616625 - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Recruiting NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT05700994 - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) N/A
Completed NCT04109014 - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk N/A
Completed NCT01822132 - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade N/A
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Active, not recruiting NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2